Saving Hearts, Kidneys and Lives in Type 2 Diabetes - Results from the FLOW Trial

Show notes

The FLOW study continues to deliver groundbreaking insights into the benefits of GLP-1 receptor agonists for chronic kidney disease (CKD) in people with type 2 diabetes. In this episode, experts discuss the latest findings, revealing a 24% reduction in kidney disease progression, 18% reduction in major adverse cardiovascular events (MACE), and 20% reduction in total mortality - proving that this treatment saves hearts, kidneys, and lives.

Watch the full video on YouTube to learn how GLP-1 receptor agonists provide metabolic, cardiovascular, and renal benefits across different CKD stages, why early intervention is key, and how new research is uncovering the mechanisms behind these effects.

You can also explore more about our speakers; Prof. Richard Pratley, Prof. Peter Rossing and Prof. Katherine Tuttle or watch the full session on the EASD Media Centre for more insights.

New comment

Your name or nickname, will be shown publicly
At least 10 characters long
By submitting your comment you agree that the content of the field "Name or nickname" will be stored and shown publicly next to your comment. Using your real name is optional.